Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions
CA 2459348 C · Owner: Intreat Pty Limited · Inventors: Barden, Julian Alexander; Gidley-Baird, Angus
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention concerns a wide range of diseases and conditions including , cancers. The invention provides a probe for detection of such a disease or condition. The probe is able to distinguish between functional P2X7 receptors and non-functional P2X7 receptors. The probe can do this in various ways one , of which is detecting change in relation to binding of adenosine triphosphate (ATP) to the receptors. The invention also provides a method for detecting the disease or condition, using the probe. The invention extends to treatment of the disease or condition, using an antibody or an epitope capable of , generating the antibody which can distinguish between functional and nonfunctional …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 3, 2002 and granted June 18, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 3, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 3, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.